EyePoint, Inc.

Stocks

Market Closed - Nasdaq 23:00:00 30/10/2026 +03			5-day change	1st Jan Change
0.3484 ^USD	-8.32%		-13.87%	-98.09%

10-20	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
10-20	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT

Published on 10/19/2026 at 05:50 pm +03

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, thank you for standing by. Welcome to EyePoint's LUCIA Topline Data Readout. [Operator Instructions] Please be advised that

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-20	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
10-20	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT
10-20	Laidlaw Downgrades EyePoint Pharmaceuticals to Hold From Buy	MT
10-20	JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral	MT
10-20	RBC Capital Adjusts Price Target on EyePoint Pharmaceuticals to $1 From $5, Keeps Sector Perform, Speculative Risk	MT
10-20	Mizuho Downgrades EyePoint Pharmaceuticals to Neutral From Outperform, Adjusts PT to $0.50 From $39	MT
10-20	Betta Pharmaceuticals Partner's Phase 3 Trials for Retinal Disease Treatment Fail Pre-Specified Primary Endpoint	MT
10-20	EyePoint, Inc. Reduces Workforce by Approximately 53% of Employees	CI
10-20	EyePoint, Inc. Announces Strategic Prioritization To Focus Resources On Late-Stage Program For DURAVYU In Diabetic Macular Edema	CI
10-19	Top Midday Decliners	MT
10-19	EyePoint, Inc. Announces Topline Results From LUCIA, The Second Pivotal Phase 3 Clinical Trial Of DURAVYU In Wet AMD	CI
10-19	Guggenheim Downgrades EyePoint to Neutral From Buy	MT
10-19	EyePoint, Inc. - Special Call
10-19	Jefferies Downgrades EyePoint Pharmaceuticals to Hold From Buy, $1 Price Target	MT
10-19	Global markets live: Eli Lilly, Tesla, KKR, Rheinmetall…

Duration

Period

Sector